Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019 - 2020)
Kymera Therapeutics (KYMR) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $5.9 million as the latest value for Q2 2020.
- For Q2 2020, Preferred Stock Liabilities changed N/A year-over-year to $5.9 million; the TTM value through Jun 2020 reached $5.9 million, changed N/A, while the annual FY2019 figure was $5.9 million, N/A changed from the prior year.
- Preferred Stock Liabilities hit $5.9 million in Q2 2020 for Kymera Therapeutics, roughly flat from $5.9 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $5.9 million in Q3 2019 and bottomed at $5.9 million in Q3 2019.